Skip to content

The Clinical Study of Danyu Hemai Granules for the Treatment of Primary Hypertension

The Clinical Study of Danyu Hemai Granules for the Treatment of Primary Hypertension

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001104
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension

Interventions

Experimental Group:Basic Western medicine treatment + Danyu Hemai granules
Control Group:Western medicine basic treatment + Danyu Hemai placebo granules

Sponsors

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 4.1 Outpatients or inpatients with primary hypertension of grade 1 or 2, who have either never taken antihypertensive medications or are currently taking them but still have blood pressure within 140/90 to 179/109 mmHg; 4.2 Aged between 18 and 80 years, with no restriction on gender; 4.3 Patients with concurrent yang exuberance, blood stasis, and phlegm turbidity syndrome; 4.4 Volunteers who, after fully understanding the content of this research, agree to participate and sign the informed consent form.

Exclusion criteria

Exclusion criteria: 5.1 Pregnant women, those planning pregnancy in the near future, or breastfeeding women; 5.2 Severe impairment of heart, liver, or kidney function, or other serious, life-threatening systemic diseases; 5.3 Subjects who are unable to cooperate; 5.4 Those currently participating in other clinical studies; 5.5 Allergic to the investigational drug; 5.6 History of myocardial infarction or significant stroke in the past six months; 5.7 Other conditions deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

MeasureTime frame
blood pressure;

Secondary

MeasureTime frame
TCM Syndrome Score;Echocardiogram;Urinary microalbumin;urinary creatinine;Fasting Blood Glucose;Fasting Insulin;Triglyceride;Cholesterol;Low-Density Lipoprotein;High-Density Lipoprotein;soluble growth-stimulating expression gene 2 protein;electrocardiogram;Blood Routine;Urinalysis;Stool Routine;creatinine;Urea nitrogen;Uric acid;Alanine Aminotransferase;Aspartate aminotransferase;Total Bilirubin;Albumin;

Countries

China

Contacts

Public ContactFu Deyu

Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine

12025263@shutcm.edu.cn021-65161782

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026